表紙
市場調查報告書
商品編碼
969389

呼吸道抗病毒治療市場:全球行業分析,市場規模,市場份額,增長,趨勢,預測(2020-2030年)

Respiratory Antiviral Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

出版日期: | 出版商: Transparency Market Research | 英文 204 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告調查了全球呼吸道抗病毒治療市場,提供了有關市場動態的信息,例如全球市場概況,增長因素,市場趨勢,挑戰和市場結構,以及按細分市場和地區劃分的市場。我們提供主要公司的分析和資料。

目錄

第1章序言

第2章先決條件和調查方法

第3章執行摘要

第4章市場概述

  • 簡介
  • 主要產業發展
  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
  • 全球呼吸抗病毒治療市場預測
  • 全球呼吸抗病毒治療市場展望

第5章市場前景

  • 管道分析
  • 世界主要國家的疾病流行率
  • COVID-19的影響分析

第6章全球呼吸道抗病毒治療市場分析:按藥物類別

  • 簡介
  • 市場份額/吸引力分析:按藥品類別
  • 市場預測:按藥品類別
    • 核甘類似物
    • 神經氨酸□抑製劑
    • 離子通道阻滯劑
    • 融合蛋白抑製劑
  • 市場分析:按藥品類別

第7章全球呼吸道抗病毒治療市場分析:按疾病類型劃分

  • 簡介
  • 市場份額/吸引力分析:按疾病類型
  • 市場預測:按疾病類型
    • 流感
    • 支氣管炎
    • 肺炎
    • 上呼吸道感染(URTI)
    • 其他(例如Hashika)
  • 市場分析:按疾病類型

第8章全球呼吸道抗病毒治療市場分析:按分銷渠道

  • 簡介
  • 市場份額/吸引力分析:按分銷渠道
  • 市場預測:按分銷渠道
    • 醫院藥房
    • 零售藥房
    • 在線藥房
  • 市場分析:按分銷渠道

第9章全球呼吸道抗病毒治療市場分析:按地區

  • 世界市場情景:按地區/國家
  • 市場份額/吸引力分析:按地區
  • 市場預測:按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東/非洲

第10章北美呼吸道抗病毒治療市場分析

  • 北美市場概述
  • 市場份額/吸引力分析:按國家
  • 市場預測:按國家
    • 美國
    • 加拿大
  • 市場份額/吸引力分析:按藥品類別
  • 市場預測:按藥品類別
    • 核甘類似物
    • 神經氨酸□抑製劑
    • 離子通道阻滯劑
    • 融合蛋白抑製劑
  • 市場份額/吸引力分析:按疾病類型
  • 市場預測:按疾病類型
    • 流感
    • 支氣管炎
    • 肺炎
    • 上呼吸道感染(URTI)
    • 其他(例如Hashika)
  • 市場份額/吸引力分析:按分銷渠道
  • 市場預測:按分銷渠道
    • 醫院藥房
    • 零售藥房
    • 在線藥房

第11章歐洲呼吸道抗病毒治療市場分析

第12章亞太地區呼吸道抗病毒治療市場分析

第13章拉美呼吸道抗病毒治療市場分析

第14章中東和非洲的呼吸道抗病毒治療市場分析

第15章競爭情況

  • 競爭矩陣
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Mylan, Inc.
    • Merck & Co., Inc.
    • AstraZeneca plc.
目錄
Product Code: TMRGL77000

Title:
Respiratory Antiviral Treatment Market (Drug Class: Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, and Fusion Protein Inhibitors; Disease Type: Influenza, Bronchiolitis, Pneumonia, Upper Respiratory Tract Infections (URTIs), and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030.

Respiratory Antiviral Treatment Market - Scope of the Report

TMR's report on the global respiratory antiviral treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory antiviral treatment market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global respiratory antiviral treatment market from 2020 to 2030.

The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the respiratory antiviral treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the respiratory antiviral treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global respiratory antiviral treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory antiviral treatment market.

The report delves into the competition landscape of the global respiratory antiviral treatment market. Key players operating in the global respiratory antiviral treatment market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory antiviral treatment market profiled in this report.

Key Questions Answered in Respiratory Antiviral Treatment Market Report

What is the sales/revenue generated by respiratory antiviral treatment across all regions during the forecast period?

What are the opportunities in the global respiratory antiviral treatment market?

What are the major drivers, restraints, opportunities, and threats in the market?

Which regional market is set to expand at the fastest CAGR during the forecast period?

Which drug class segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?

What are the market positions of different companies operating in the global market?

Respiratory Antiviral Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global respiratory antiviral treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory antiviral treatment market in terms of drug class, disease type, distribution channel, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory antiviral treatment market.

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Key Industry Developments
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunity
  • 4.4. Global Respiratory Antiviral Treatment Market Forecast
  • 4.5. Global Respiratory Antiviral Treatment Market Outlook

5. Market Outlook

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence Rate Globally with Key Countries
  • 5.3. COVID-19 Impact Analysis

6. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class

  • 6.1. Introduction
  • 6.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
  • 6.3. Global Respiratory Antiviral Treatment Market Forecast, by Drug Class
    • 6.3.1. Nucleoside Analogs
      • 6.3.1.1. Ribavirin
      • 6.3.1.2. Aciclovir
      • 6.3.1.3. Others
    • 6.3.2. Neuraminidase Inhibitors
      • 6.3.2.1. Oseltamivir
      • 6.3.2.2. Zanamivir
      • 6.3.2.3. Others
    • 6.3.3. Ion Channel Blockers
    • 6.3.4. Fusion Protein Inhibitors
  • 6.4. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class

7. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type

  • 7.1. Introduction
  • 7.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
  • 7.3. Global Respiratory Antiviral Treatment Market Forecast, by Disease Type
    • 7.3.1. Influenza
    • 7.3.2. Bronchiolitis
    • 7.3.3. Pneumonia
    • 7.3.4. Upper Respiratory Tract Infections (URTIs)
    • 7.3.5. Others (measles, etc.)
  • 7.4. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type

8. Global Respiratory Antiviral Treatment Market Analysis, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 8.3. Global Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Global Respiratory Antiviral Treatment Market Analysis, by Route of Administration

9. Global Respiratory Antiviral Treatment Market Analysis, by Region

  • 9.1. Global Respiratory Antiviral Treatment Market Scenario, by Region/Country
  • 9.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Region
  • 9.3. Global Respiratory Antiviral Treatment Market Forecast, by Region
    • 9.3.1. North America
    • 9.3.2. Europe
    • 9.3.3. Asia Pacific
    • 9.3.4. Latin America
    • 9.3.5. Middle East & Africa

10. North America Respiratory Antiviral Treatment Market Analysis

  • 10.1. North America Respiratory Antiviral Treatment Market Overview
  • 10.2. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country
  • 10.3. North America Respiratory Antiviral Treatment Market Forecast, by Country
    • 10.3.1. U.S.
    • 10.3.2. Canada
  • 10.4. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
  • 10.5. North America Respiratory Antiviral Treatment Market Forecast, by Drug Class
    • 10.5.1. Nucleoside Analogs
      • 10.5.1.1. Ribavirin
      • 10.5.1.2. Aciclovir
      • 10.5.1.3. Others
    • 10.5.2. Neuraminidase Inhibitors
      • 10.5.2.1. Oseltamivir
      • 10.5.2.2. Zanamivir
      • 10.5.2.3. Others
    • 10.5.3. Ion Channel Blockers
    • 10.5.4. Fusion Protein Inhibitors
  • 10.6. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
  • 10.7. North America Respiratory Antiviral Treatment Market Forecast, by Disease Type
    • 10.7.1. Influenza
    • 10.7.2. Bronchiolitis
    • 10.7.3. Pneumonia
    • 10.7.4. Upper Respiratory Tract Infections (URTIs)
    • 10.7.5. Others (measles, etc.)
  • 10.8. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 10.9. North America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
    • 10.9.1. Hospital Pharmacies
    • 10.9.2. Retail Pharmacies
    • 10.9.3. Online Pharmacies

11. Europe Respiratory Antiviral Treatment Market Analysis

  • 11.1. Europe Respiratory Antiviral Treatment Market Overview
  • 11.2. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 11.3. Europe Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
    • 11.3.1. Germany
    • 11.3.2. France
    • 11.3.3. U.K.
    • 11.3.4. Italy
    • 11.3.5. Spain
    • 11.3.6. Rest of Europe
  • 11.4. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
  • 11.5. Europe Respiratory Antiviral Treatment Market Forecast, by Drug Class
    • 11.5.1. Nucleoside Analogs
      • 11.5.1.1. Ribavirin
      • 11.5.1.2. Aciclovir
      • 11.5.1.3. Others
    • 11.5.2. Neuraminidase Inhibitors
      • 11.5.2.1. Oseltamivir
      • 11.5.2.2. Zanamivir
      • 11.5.2.3. Others
    • 11.5.3. Ion Channel Blockers
    • 11.5.4. Fusion Protein Inhibitors
  • 11.6. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
  • 11.7. Europe Respiratory Antiviral Treatment Market Forecast, by Disease Type
    • 11.7.1. Influenza
    • 11.7.2. Bronchiolitis
    • 11.7.3. Pneumonia
    • 11.7.4. Upper Respiratory Tract Infections (URTIs)
    • 11.7.5. Others (measles, etc.)
  • 11.8. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 11.9. Europe Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
    • 11.9.1. Hospital Pharmacies
    • 11.9.2. Retail Pharmacies
    • 11.9.3. Online Pharmacies

12. Asia Pacific Respiratory Antiviral Treatment Market Analysis

  • 12.1. Asia Pacific Respiratory Antiviral Treatment Market Overview
  • 12.2. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 12.3. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
    • 12.3.1. Japan
    • 12.3.2. China
    • 12.3.3. India
    • 12.3.4. Australia & New Zealand
    • 12.3.5. Rest of Asia Pacific
  • 12.4. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
  • 12.5. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Drug Class
    • 12.5.1. Nucleoside Analogs
      • 12.5.1.1. Ribavirin
      • 12.5.1.2. Aciclovir
      • 12.5.1.3. Others
    • 12.5.2. Neuraminidase Inhibitors
      • 12.5.2.1. Oseltamivir
      • 12.5.2.2. Zanamivir
      • 12.5.2.3. Others
    • 12.5.3. Ion Channel Blockers
    • 12.5.4. Fusion Protein Inhibitors
  • 12.6. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
  • 12.7. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Disease Type
    • 12.7.1. Influenza
    • 12.7.2. Bronchiolitis
    • 12.7.3. Pneumonia
    • 12.7.4. Upper Respiratory Tract Infections (URTIs)
    • 12.7.5. Others (measles, etc.)
  • 12.8. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 12.9. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
    • 12.9.1. Hospital Pharmacies
    • 12.9.2. Retail Pharmacies
    • 12.9.3. Online Pharmacies

13. Latin America Respiratory Antiviral Treatment Market Analysis

  • 13.1. Latin America Respiratory Antiviral Treatment Market Overview
  • 13.2. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 13.3. Latin America Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
    • 13.3.1. Brazil
    • 13.3.2. Mexico
    • 13.3.3. Rest of Latin America
  • 13.4. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
  • 13.5. Latin America Respiratory Antiviral Treatment Market Forecast, by Drug Class
    • 13.5.1. Nucleoside Analogs
      • 13.5.1.1. Ribavirin
      • 13.5.1.2. Aciclovir
      • 13.5.1.3. Others
    • 13.5.2. Neuraminidase Inhibitors
      • 13.5.2.1. Oseltamivir
      • 13.5.2.2. Zanamivir
      • 13.5.2.3. Others
    • 13.5.3. Ion Channel Blockers
    • 13.5.4. Fusion Protein Inhibitors
  • 13.6. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
  • 13.7. Latin America Respiratory Antiviral Treatment Market Forecast, by Disease Type
    • 13.7.1. Influenza
    • 13.7.2. Bronchiolitis
    • 13.7.3. Pneumonia
    • 13.7.4. Upper Respiratory Tract Infections (URTIs)
    • 13.7.5. Others (measles, etc.)
  • 13.8. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 13.9. Latin America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
    • 13.9.1. Hospital Pharmacies
    • 13.9.2. Retail Pharmacies
    • 13.9.3. Online Pharmacies

14. Middle East & Africa Respiratory Antiviral Treatment Market Analysis

  • 14.1. Middle East & Africa Respiratory Antiviral Treatment Market Overview
  • 14.2. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 14.3. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
    • 14.3.1. GCC Countries
    • 14.3.2. South Africa
    • 14.3.3. Rest of Middle East & Africa
  • 14.4. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
  • 14.5. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Drug Class
    • 14.5.1. Nucleoside Analogs
      • 14.5.1.1. Ribavirin
      • 14.5.1.2. Aciclovir
      • 14.5.1.3. Others
    • 14.5.2. Neuraminidase Inhibitors
      • 14.5.2.1. Oseltamivir
      • 14.5.2.2. Zanamivir
      • 14.5.2.3. Others
    • 14.5.3. Ion Channel Blockers
    • 14.5.4. Fusion Protein Inhibitors
  • 14.6. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
  • 14.7. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Disease Type
    • 14.7.1. Influenza
    • 14.7.2. Bronchiolitis
    • 14.7.3. Pneumonia
    • 14.7.4. Upper Respiratory Tract Infections (URTIs)
    • 14.7.5. Others (measles, etc.)
  • 14.8. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 14.9. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
    • 14.9.1. Hospital Pharmacies
    • 14.9.2. Retail Pharmacies
    • 14.9.3. Online Pharmacies

15. Competition Landscape

  • 15.1. Competition Matrix
  • 15.2. Company Profiles
    • 15.2.1. F. Hoffmann-La Roche Ltd.
      • 15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.1.2. Financial Overview
      • 15.2.1.3. Product Portfolio
      • 15.2.1.4. SWOT Analysis
      • 15.2.1.5. Strategic Overview
    • 15.2.2. Novartis AG
      • 15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.2.2. Financial Overview
      • 15.2.2.3. Product Portfolio
      • 15.2.2.4. SWOT Analysis
      • 15.2.2.5. Strategic Overview
    • 15.2.3. Takeda Pharmaceutical Company Limited
      • 15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.3.2. Financial Overview
      • 15.2.3.3. Product Portfolio
      • 15.2.3.4. SWOT Analysis
      • 15.2.3.5. Strategic Overview
    • 15.2.4. Pfizer, Inc.
      • 15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.4.2. Product Portfolio
      • 15.2.4.3. SWOT Analysis
      • 15.2.4.4. Strategic Overview
    • 15.2.5. Teva Pharmaceutical Industries Ltd.
      • 15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.5.2. Financial Overview
      • 15.2.5.3. Product Portfolio
      • 15.2.5.4. SWOT Analysis
      • 15.2.5.5. Strategic Overview
    • 15.2.6. Sun Pharmaceutical Industries Ltd.
      • 15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.6.2. Financial Overview
      • 15.2.6.3. Product Portfolio
      • 15.2.6.4. SWOT Analysis
      • 15.2.6.5. Strategic Overview
    • 15.2.7. GlaxoSmithKline plc
      • 15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.7.2. Financial Overview
      • 15.2.7.3. Product Portfolio
      • 15.2.7.4. SWOT Analysis
      • 15.2.7.5. Strategic Overview
    • 15.2.8. Mylan, Inc.
      • 15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.8.2. Financial Overview
      • 15.2.8.3. Product Portfolio
      • 15.2.8.4. SWOT Analysis
      • 15.2.8.5. Strategic Overview
    • 15.2.9. Merck & Co., Inc.
      • 15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.9.2. Financial Overview
      • 15.2.9.3. Product Portfolio
      • 15.2.9.4. SWOT Analysis
      • 15.2.9.5. Strategic Overview
    • 15.2.10. AstraZeneca plc.
      • 15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.10.2. Financial Overview
      • 15.2.10.3. Product Portfolio
      • 15.2.10.4. SWOT Analysis
      • 15.2.10.5. Strategic Overview

List of Tables

  • Table 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 02: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018-2030
  • Table 03: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018-2030
  • Table 04: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 05: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 06: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Region, 2018-2030
  • Table 07: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country, 2018-2030
  • Table 08: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 09: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018-2030
  • Table 10: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018-2030
  • Table 11: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 12: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 13: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 14: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 15: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018-2030
  • Table 16: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018-2030
  • Table 17: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 18: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 19: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 20: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 21: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018-2030
  • Table 22: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018-2030
  • Table 23: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 24: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 25: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 26: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 27: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018-2030
  • Table 28: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018-2030
  • Table 29: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 30: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 31: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 32: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
  • Table 33: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018-2030
  • Table 34: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018-2030
  • Table 35: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 36: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030

List of Figures

  • Figure 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 02: Global Respiratory Antiviral Treatment Market Value Share, by Drug Class, 2019
  • Figure 03: Global Respiratory Antiviral Treatment Market Value Share, by Distribution Channel, 2019
  • Figure 04: Global Respiratory Antiviral Treatment Market Value Share, by Disease Type, 2019
  • Figure 05: Global Respiratory Antiviral Treatment Market Value Share, by Region, 2019
  • Figure 06: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 07: Global Respiratory Antiviral Treatment Market Attractiveness, by Drug Class, 2020-2030
  • Figure 08: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Nucleoside Analogs, 2018-2030
  • Figure 09: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Neuraminidase Inhibitors, 2018-2030
  • Figure 10: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Ion Channel Blockers, 2018-2030
  • Figure 11: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Fusion Protein Inhibitors, 2018-2030
  • Figure 12: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
  • Figure 13: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 14: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Influenza, 2018-2030
  • Figure 15: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Bronchiolitis, 2018-2030
  • Figure 16: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Pneumonia, 2018-2030
  • Figure 17: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Upper Respiratory Tract Infections (URTIs), 2018-2030
  • Figure 18: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Others (Measles, etc.), 2018-2030
  • Figure 19: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 20: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 21: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2018-2030
  • Figure 22: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2018-2030
  • Figure 23: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2018-2030
  • Figure 24: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Region, 2019 and 2030
  • Figure 25: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Region
  • Figure 26: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 27: North America Respiratory Antiviral Treatment Market Value Share (%), by Country, 2019 and 2030
  • Figure 28: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country, 2020-2030
  • Figure 29: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 30: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 31: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
  • Figure 32: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 33: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 34: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 35: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 36: Europe Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
  • Figure 37: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 38: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 39: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 40: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
  • Figure 41: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 42: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 43: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 44: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 45: Asia Pacific Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
  • Figure 46: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 47: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 48: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 49: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
  • Figure 50: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 51: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 52: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 53: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 54: Latin America Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
  • Figure 55: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 56: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 57: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 58: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
  • Figure 59: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 60: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 61: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 62: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 63: Middle East & Africa Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
  • Figure 64: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 65: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
  • Figure 66: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020-2030
  • Figure 67: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
  • Figure 68: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 69: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 70: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030